-
America's Cup switches to two-year cycle
-
Jesus could start for Arsenal in League Cup, says Arteta
-
EU to probe Czech aid for two nuclear units
-
Strauss says sacking Stokes and McCullum will not solve England's Ashes woes
-
Noel takes narrow lead after Alta Badia slalom first run
-
Stocks diverge as rate hopes rise, AI fears ease
-
Man City players face Christmas weigh-in as Guardiola issues 'fatty' warning
-
German Christmas markets hit by flood of fake news
-
Liverpool fear Isak has broken leg: reports
-
West Indies captain says he 'let the team down' in New Zealand Tests
-
Thailand says Cambodia agrees to border talks after ASEAN meet
-
Alleged Bondi shooters conducted 'tactical' training in countryside, Australian police say
-
Swiss court to hear landmark climate case against cement giant
-
Knicks' Brunson scores 47, Bulls edge Hawks epic
-
Global nuclear arms control under pressure in 2026
-
Asian markets rally with Wall St as rate hopes rise, AI fears ease
-
Jailed Malaysian ex-PM Najib loses bid for house arrest
-
Banned film exposes Hong Kong's censorship trend, director says
-
Duffy, Patel force West Indies collapse as NZ close in on Test series win
-
Australian state pushes tough gun laws, 'terror symbols' ban after shooting
-
A night out on the town during Nigeria's 'Detty December'
-
US in 'pursuit' of third oil tanker in Caribbean: official
-
CO2 soon to be buried under North Sea oil platform
-
Steelers edge Lions as Bears, 49ers reach playoffs
-
India's Bollywood counts costs as star fees squeeze profits
-
McCullum admits errors in Ashes preparations as England look to salvage pride
-
Pets, pedis and peppermints: When the diva is a donkey
-
'A den of bandits': Rwanda closes thousands of evangelical churches
-
Southeast Asia bloc meets to press Thailand, Cambodia on truce
-
As US battles China on AI, some companies choose Chinese
-
AI resurrections of dead celebrities amuse and rankle
-
EonX Announces Update To Loan Facility
-
Silver X Mining Announces Management Update
-
Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform
-
Revolve Receives Generation Permit Approval for 130 MW El 24 Wind Project in Mexico
-
NuRAN Restores Sites in Ghana and Resumes Network Deployment Activities in the Democratic Republic of the Congo
-
1933 Industries Issues Final Reminder to 2024 Debenture Holders: December 22 Is the Deadline to Convert
-
Arrive AI to Attend CES 2026 to Engage Industry Leaders on the Future of Autonomous Delivery and AI-Driven Logistics
-
Guanajuato Silver Receives TSXV Conditional Approval for Bolanitos Acquisition
-
Brenmiller Energy CEO Avi Brenmiller Issues Year-End Letter to Shareholders
-
1933 Industries Achieves Positive Income in Q1 2026, Marking Third Consecutive Profitable Quarter
-
New Joint Initiative to Tackle Core Identity Challenge For The Global Precious Metals Industry
-
Best Western Plus Lamplighter Inn & Conference Centre recognized with 2026 Consumer Choice Award for Hotel in London
-
CoTec Investment MagIron Acquires Reynolds Pellet Plant and Launches United States Based DR Grade Pellet and Merchant Pig Iron Strategy
-
Saat & Saat Acquires Turkish Apparel Leader Aydinli Group, Expanding U.S. Polo Assn. Markets Across Turkey, the Middle East, Eastern Europe, and North Africa
-
EON Resources Inc. Reports Management and Directors Buy an Additional 282,000 Shares of EON Class A Common Stock for a Total of 1,561,000 Shares Bought in 2025 and a Total Ownership of Over 5 million Shares
-
Heirs Energies Agrees $750m Afreximbank Financing to Drive Long-Term Growth
-
Black Book Poll: "Governed AI" Emerges as the Deciding Factor in 2026 NHS Procurement
-
Hemogenyx Pharmaceuticals PLC Announces Update on Admission of Shares
-
Pantheon Resources PLC Announces Shareholder Letter and Corporate Update on Dubhe-1
ADM Tronics Reports First Quarter of Fiscal Year 2026 Results
NORTHVALE, NJ / ACCESS Newswire / August 19, 2025 / ADM Tronics Unlimited, Inc. (OTCQB:ADMT), a technology-based developer and manufacturer of innovative technologies and products, announces results for its first fiscal quarter ended June 30, 2025 of Fiscal Year 2025.
The upward trend in revenues, as reported in the Company's Annual 10-K Report for the fiscal year ended March 31, 2025, continues for this first fiscal quarter ended June 30, 2025 of the fiscal year ended March 31, 2026, ADMT had an increase of over 13% in revenues for the quarter ended June 30, 2025, as compared to the same period last year. ADMT's increase in revenues for the quarter ended June 30, 2025 was primarily due to an increase in revenues of over 25% in its electronics segment coupled with an increase of approximately 5% in the chemical segment, offset by a reduction of 2% in engineering segment revenues as compared to the same period last year. Income from operations was $109,234 for the quarter ended June 30, 2025 as compared to $164,281 for the quarter ended June 30, 2024 an increase of approximately 8% offset by a decrease of approximately 2% in research and development. Net income was $327,634 for the quarter ended June 30, 2025 as compared to $272,168 for the same period last year.
During the quarter ended June 30, 2025, ADMT continued research and development efforts on the medical version of the Sonotron® for use on humans where the need for effective pain treatment without the use of drugs or opioids is very large and unmet. As previously reported, this non-invasive therapy technology utilizes pulsed radio frequency output for the treatment of chronic and acute musculoskeletal pain conditions such as osteoarthritis, tendonitis, and other conditions and diseases. The company plans on pursuing a 510(k) submission to the FDA when development of the human medical version is completed. The Company commercially introduced the Vet-Sonotron®, a professional veterinary version of this technology for treatment of animals, and continues to seek national or regional distributors for sales and marketing to the small animal and equine veterinary markets.
Revenues for the quarter ended June 30, 2025, were $973,675 as compared to $857,845 for the same period last year, an increase of 13.5%. Income from operations for June 30, 2025 was $109,234 as compared to $164,281 for the same period last year. Complete financial results are available in the Company's Quarterly Report on Form 10Q for June 30, 2025, available at www.sec.gov.
Financial Highlights
Three Months Ended | Three Months Ended | |||
June 30, 2025 | June 30, 2024 | |||
Net Revenues | $ | 973,675 | $ | 857,845 |
Cost of sales | 492,382 | 336,942 | ||
Gross Profit | 481,293 | 520,903 | ||
Operating expenses: | ||||
Research and development | 125,589 | 127,993 | ||
Selling, general and administrative | 246,470 | 228,629 | ||
Total operating expenses | 372,059 | 356,622 | ||
Income from operations | 109,234 | 164,281 | ||
Total other income | 219,900 | 108,387 | ||
Income before provision for taxes | 329,134 | 272,668 | ||
Total provision for income taxes | 1,500 | 500 | ||
Net income | $ | 327,634 | $ | 272,168 |
Basic and diluted earnings (loss) per common share | $ | 0.00 | $ | 0.00 |
Weighted average shares of common stock outstanding - basic and diluted | 67,588,492 | 67,588,492 | ||
About ADMT
ADMT is a diversified, technology-based developer and manufacturer of innovative technologies and products. Its core competency is its ability to conceptualize a technology, bring it through development, into manufacturing and commercialization, all in-house. ADMT has three areas of activity: Proprietary Electronic Medical Devices; Design, Engineering, Regulatory and Manufacturing Services; and, Eco-Friendly, Safe, Water-Based Formulations. The Company's headquarters, laboratories, and FDA-Registered medical device manufacturing operations are located in Northvale, NJ. ADMT's multi-disciplinary team of engineers, researchers and technologists utilize advanced technology infrastructure, for the research, development and commercialization of diversified technologies. Additional information is available at admtronics.com
ADMT welcomes inquiries for its electronics and medical device contract engineering and manufacturing services at www.admteng.com.
To receive ADMT email updates, complete form at https://admtronics.com/investor-relations/
Sonotron® is a registered trademark of ADM Tronics Unlimited, Inc. vet-sonotron.com
Except for historical information contained herein, the matters set forth in this news release are "forward-looking" statements (as defined in the Private Securities Litigation Reform Act of 1995), including statements regarding future revenue growth and performance. Although ADMT believes the expectations reflected in such forward-looking statements are based upon reasonable assumptions, there can be no assurance that its expectations will be realized. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from expectations. Factors that could contribute to such differences include those described from time to time in ADMT's filings with the SEC, news releases and other communications. The Company assumes no obligation to update the information contained in this news release.
Contact: Andre' DiMino 201-767-6040, [email protected]
SOURCE: ADM Tronics Unlimited Inc.
View the original press release on ACCESS Newswire
P.Mathewson--AMWN